JPS6053016B2 - Novel 3,4-dihydrocarbostyryl derivative - Google Patents

Novel 3,4-dihydrocarbostyryl derivative

Info

Publication number
JPS6053016B2
JPS6053016B2 JP51104091A JP10409176A JPS6053016B2 JP S6053016 B2 JPS6053016 B2 JP S6053016B2 JP 51104091 A JP51104091 A JP 51104091A JP 10409176 A JP10409176 A JP 10409176A JP S6053016 B2 JPS6053016 B2 JP S6053016B2
Authority
JP
Japan
Prior art keywords
dihydrocarbostyryl
reaction
acetyl
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51104091A
Other languages
Japanese (ja)
Other versions
JPS5328180A (en
Inventor
靖男 大城
量之 中川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP51104091A priority Critical patent/JPS6053016B2/en
Publication of JPS5328180A publication Critical patent/JPS5328180A/en
Publication of JPS6053016B2 publication Critical patent/JPS6053016B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明は新規な3・4−ジヒドロカルボスチリル誘導体
に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to novel 3,4-dihydrocarbostyryl derivatives.

本発明の誘導体は一般式 0CH2CHCH2NR3R4 R ]。The derivatives of the present invention have the general formula 0CH2CHCH2NR3R4 R].

Cl〕R、H 〔式中R、は水素原子又はハロゲン原子、R。Cl]R,H [In the formula, R is a hydrogen atom or a halogen atom, R.

はアセチル基、並びにR。及びR、はいずれか一方が水
素原子を、他方が低級アルキル基、アルキル部分の炭素
数が1〜6であるフェニルアルキル基、フェニル環上に
低級アルコキシ基を有しアルキル部分の炭素数が1〜6
であるフェニルアルキル基又はフェニル環上に低級アル
コキシ基を有しアルキル部分の炭素数が1〜6であるフ
ェノキシアルキル基を示す。〕で表わされる。
is an acetyl group, and R is an acetyl group. and R, one of which has a hydrogen atom, the other a lower alkyl group, a phenylalkyl group whose alkyl moiety has 1 to 6 carbon atoms, and a lower alkoxy group on the phenyl ring and whose alkyl moiety has 1 carbon number. ~6
represents a phenylalkyl group or a phenoxyalkyl group having a lower alkoxy group on the phenyl ring and having 1 to 6 carbon atoms in the alkyl moiety. ].

上記一般式〔I〕においてハロゲン原子としては、塩素
原子、臭素原子、沃素原子、弗素原子等・を例示できる
In the above general formula [I], examples of the halogen atom include a chlorine atom, a bromine atom, an iodine atom, a fluorine atom, and the like.

また上記一般式〔I〕において低級アルキル基としては
炭素数が1〜6個の直鎖状若しくは分枝状のアルキル基
を例示でき、具体的にはメチル、エチル、プロピル、イ
ソプロピル、ブチル、イソ9ブチル、sec−ブチル、
tert−ブチル、ペンチル、ヘキシル等を例示できる
In addition, in the above general formula [I], examples of the lower alkyl group include linear or branched alkyl groups having 1 to 6 carbon atoms, specifically methyl, ethyl, propyl, isopropyl, butyl, and isopropyl. 9-butyl, sec-butyl,
Examples include tert-butyl, pentyl, hexyl and the like.

フェニル環に低級アルコキシ基を有し若しくは有さず且
つアルキル部分の炭素数が1〜6であるフェニルアルキ
ル基としては、炭素数1〜6の直鎖状若しくは分枝状の
アルキレン基と、フェニル基または1〜3個の同一若し
くは相異なるアルコキシ基を有するフェニル基とが結合
したものを例示でき、該低級アルコキシ基としてはメト
キシ、エトキシ、プロポキシ、イソプロポキシ、ブトキ
シ等を例示できる。またフェニル環に低級アルコキシ基
を有するアルキル部分の炭素数が1〜6であるフェノキ
シアルキル基としては、上記フェニルアルキル基と同様
のアルキレン基と低級アルコキシ基を有するフェニル基
とが酸素原子を介して結合したものを例示でき、例えば
2−フェノキシエチル、2−(4ーメトキシフェノキシ
)エチル、1−メチルー3−フェノキシプロピル、3−
(3・4・5−トリメトキシフェノキシ)ブチル等を例
示できる。本発明はまた上記一般式〔1〕で表わされる
新規な3・4−ジヒドロカルボスチリル誘導体の酸−付
加塩、特に薬理的に許容される酸付加塩を包含する。本
発明の化合物はβ−アドレナリン作働阻害作用を有し、
不整脈、狭心症等の心臓病薬、抗高血圧薬等として有用
性の期待できるものである。以下本発明化合物の代表例
を挙げる。6−アセチルー5−(3−Tert−ブチル
アミノー2−ヒドロキシ)プロポキシー3●4−ジヒド
ロカルボスチリル、6−アセチルー5−〔3−(3●4
−ジメトキシフェネチルアミノ)−2−ζヒドロキシ〕
プロポキシー3・4−ジヒドロカルボスチリル、6−ア
セチルー8−クロロー5−(3−Tert−ブチルアミ
ノー2−ヒドロキシ)プロポキシー3●4−ジヒドロカ
ルボスチリル、6−アセチルー8−クロロー5−〔3−
(3・4−ジメトキシフェネチルアミノ)−2−ヒドロ
キシ〕プロポキシー3・4−ジヒドロカルボスチリル、
7−アセチルー8−ブロモー5−(2−ヒドロキシー3
−1S0−プロピルアミノ)プロポキシー3・4−ジヒ
ドロカルボスチリル、6−アセチルー5−〔2−ヒドロ
キシー3−(3・4・5−トリメトキシフェネチルアミ
ノ)〕プロポキシー3・4−ジヒドロカルボスチリル、
8−アセチルー5−(3−Tert−ブチルアミノー2
−ヒドロキシ)プロポキシー3・4−ジヒドロカルボス
チリル、8−アセチルー6−クロロー5−(2−ヒドロ
キシー3−1S0−プロピルアミノ)プロポキシー3●
4−ジヒドロカルボスチリル、8−アセチルー6−ヨー
ドー5−(2−ヒドロキシー3一ISO−プロピルアミ
ノ)プロポキシー3・4−ジヒドロカルボスチリル、6
−アセチルー5−(2−ヒドロキシー3−(1−メチル
ー3−フェニルプロピルアミノ)〕プロポキシー3・4
−ジヒドロカルボスチリル。
Examples of phenylalkyl groups having or not having a lower alkoxy group in the phenyl ring and having 1 to 6 carbon atoms in the alkyl moiety include linear or branched alkylene groups having 1 to 6 carbon atoms, and phenyl or a phenyl group having 1 to 3 identical or different alkoxy groups, and examples of the lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, and the like. In addition, as a phenoxyalkyl group in which the alkyl moiety having a lower alkoxy group in the phenyl ring has 1 to 6 carbon atoms, an alkylene group similar to the above phenylalkyl group and a phenyl group having a lower alkoxy group are connected via an oxygen atom. For example, 2-phenoxyethyl, 2-(4-methoxyphenoxy)ethyl, 1-methyl-3-phenoxypropyl, 3-phenoxypropyl, etc.
Examples include (3,4,5-trimethoxyphenoxy)butyl. The present invention also includes acid addition salts, particularly pharmacologically acceptable acid addition salts, of the novel 3,4-dihydrocarbostyryl derivative represented by the above general formula [1]. The compound of the present invention has β-adrenergic inhibitory action,
It is expected to be useful as a drug for heart diseases such as arrhythmia and angina pectoris, and as an antihypertensive drug. Representative examples of the compounds of the present invention are listed below. 6-acetyl-5-(3-Tert-butylamino-2-hydroxy)propoxy 3●4-dihydrocarbostyryl, 6-acetyl-5-[3-(3●4
-dimethoxyphenethylamino)-2-ζhydroxy]
Propoxy 3,4-dihydrocarbostyryl, 6-acetyl-8-chloro5-(3-Tert-butylamino-2-hydroxy)propoxy3●4-dihydrocarbostyryl, 6-acetyl-8-chloro5-[3-
(3,4-dimethoxyphenethylamino)-2-hydroxy]propoxy 3,4-dihydrocarbostyryl,
7-acetyl-8-bromo-5-(2-hydroxy-3
-1S0-propylamino) propoxy 3,4-dihydrocarbostyryl, 6-acetyl-5-[2-hydroxy-3-(3,4,5-trimethoxyphenethylamino)] propoxy 3,4-dihydrocarbostyryl,
8-acetyl-5-(3-Tert-butylamino-2
-Hydroxy)propoxy 3,4-dihydrocarbostyryl, 8-acetyl-6-chloro5-(2-hydroxy-3-1S0-propylamino)propoxy 3●
4-dihydrocarbostyryl, 8-acetyl-6-iodo-5-(2-hydroxy-3-ISO-propylamino)propoxy-3,4-dihydrocarbostyryl, 6
-acetyl-5-(2-hydroxy-3-(1-methyl-3-phenylpropylamino)]propoxy 3,4
-dihydrocarbostyril.

本発明化合物は、例えば下記一般式〔■〕で表わされる
カルボスチリル誘導体を原料とし、之を下記反応式1又
は2に従いエピハロゲノヒドリン及び次いでアミン類と
反応させることにより製造し得る。
The compound of the present invention can be produced, for example, by using a carbostyryl derivative represented by the following general formula [■] as a raw material and reacting it with epihalogenohydrin and then amines according to Reaction Formula 1 or 2 below.

但し上記反応式中R1、R2、R3及びR4は上記と同
様の意味を有し、xはハロゲン原子を示すものとする。
However, in the above reaction formula, R1, R2, R3 and R4 have the same meanings as above, and x represents a halogen atom.

上記において出発原料とする一般式〔■〕で表わされる
化合物は、新規化合物であり、之等は置換基の種類及び
置換位置に応じて夫々下記反応式3に従い合成される。
但し上記においてR2は一般式〔1〕におけるそれと同
じ、及びXはハロゲン原子を示す。即ち公知の化合物5
−ヒドロキシー3・4−ジヒドロカルボスチリル〔■〕
を常法に従いアセチル化して5−アセチルオキシー3・
4−ジヒドロカルボスチリル誘導体〔■〕とした後これ
を、経路4の如く塩化アルミニウム等を触媒としてフリ
ース転位反応を行なうか、経路8−Cの如く先にハロゲ
ン化後同様にフリース転位反応を行なうか、経路4→O
の如くフリース転位反応後ハロゲン化するか、又は経路
8→O→[F]の如くハロゲン化反応後フリース転位反
応せしめ最後に脱ハロゲン化を行なうことにより容易に
収得できる。上記において化合物〔■〕のアセチル化反
応は、アセチル化剤として酸ハロゲン化物もしくは酸無
水物を用い公知の方法に従い実施できる。この反応は通
常例えば塩基性化合物の存在下行なわれ、この際使用さ
れる塩基性化合物としては金属ナトリウム、金属カリウ
ム等のアルカリ金属及び之等アルカリ金属の水酸化物、
炭酸塩、重炭酸塩或いはピリジン、ピペリジン等の芳香
族アミン化合物等が挙げられる。上記反応は無溶媒もし
くは溶媒中のいずれでも進行するが、通常は適当な溶媒
を用いて行なわれる。使用される溶媒として例えばメタ
ノール、エタノール、イソプロパノール等の低級アルコ
ール類、アセトン、メチルエチルケトン等のケトン類、
エーテル、ジオキサン等のエーテル類、ベンゼン、トル
エン、キシレン等の芳香族炭化水素類、水等が挙げられ
るが、アセトン、水を用いるのが好ましい。アセチル化
剤の使用量は化合物〔■〕に対し等モル以上であればよ
いが通常1.5〜3倍モルとするのがよい。反応は0〜
150好ましくは0〜5CfCて進行する。フリース転
位反応は触媒として通常ルイス酸例えば塩化アルミニウ
ム、塩化亜塩、塩化鉄、塩化錫等を用いて公知の方法に
より実施できる。
The compound represented by the general formula [■] used as a starting material in the above is a new compound, and is synthesized according to the following Reaction Formula 3 depending on the type and position of the substituent.
However, in the above, R2 is the same as that in general formula [1], and X represents a halogen atom. That is, known compound 5
-Hydroxy-3,4-dihydrocarbostyryl [■]
was acetylated according to a conventional method to obtain 5-acetyloxy-3.
After making the 4-dihydrocarbostyryl derivative [■], it is subjected to Fries rearrangement reaction using aluminum chloride as a catalyst as in route 4, or it is first halogenated and then subjected to Fries rearrangement reaction in the same manner as in route 8-C. Or route 4→O
It can be easily obtained by halogenation after Fries rearrangement reaction, or by halogenation reaction followed by Fries rearrangement reaction and finally dehalogenation, as in route 8→O→[F]. In the above, the acetylation reaction of compound [■] can be carried out according to a known method using an acid halide or an acid anhydride as an acetylating agent. This reaction is usually carried out, for example, in the presence of a basic compound, and the basic compounds used at this time include alkali metals such as metallic sodium and metallic potassium, hydroxides of such alkali metals,
Examples include carbonates, bicarbonates, and aromatic amine compounds such as pyridine and piperidine. Although the above reaction proceeds either without a solvent or in a solvent, it is usually carried out using a suitable solvent. Examples of solvents used include lower alcohols such as methanol, ethanol, and isopropanol; ketones such as acetone and methyl ethyl ketone;
Examples include ethers such as ether and dioxane, aromatic hydrocarbons such as benzene, toluene and xylene, and water, but it is preferable to use acetone and water. The amount of the acetylating agent used may be at least equimolar to the compound [■], but it is usually 1.5 to 3 times the molar amount. The reaction is 0~
150, preferably 0 to 5 CfC. The Fries rearrangement reaction can be carried out by a known method using a Lewis acid such as aluminum chloride, subsalt chloride, iron chloride, tin chloride, etc. as a catalyst.

この反応は無溶媒でも行われるが、溶媒として二硫化炭
素、ニトロベンゼン、エーテル、ジオキサン等を用いて
も行ない得る。反応は室温〜250℃で進行するが、一
般には50〜150℃で行うのが好ましい。ハロゲン化
反応は、酢酸、四塩化炭素、塩化メチレン、塩化エチレ
ン、クロロホルム、ピリジン等の溶媒中で、塩素、臭素
、沃素、弗素、N−ブロムこはく酸イミド、N−クロロ
こはく酸イミド等のハロゲン化剤を使用して実施できる
This reaction can be carried out without a solvent, but it can also be carried out using carbon disulfide, nitrobenzene, ether, dioxane, etc. as a solvent. The reaction proceeds at room temperature to 250°C, but is generally preferably carried out at 50 to 150°C. The halogenation reaction is performed using halogens such as chlorine, bromine, iodine, fluorine, N-bromosuccinimide, N-chlorosuccinimide, etc. in a solvent such as acetic acid, carbon tetrachloride, methylene chloride, ethylene chloride, chloroform, or pyridine. It can be carried out using a curing agent.

ハロゲン化剤の使用量は原料1モルに対し通常等モル以
上好ましくは等モルとすればよく、反応は−50〜80
℃好ましくは−10℃〜室温下に約1〜2橋間で終了す
る。脱ハロゲン化反応は、公知の接触還元反応を応用で
きる。
The amount of the halogenating agent to be used is usually equal to or more than equimolar, preferably equimolar to 1 mole of the raw material, and the reaction is -50 to 80%.
C. Preferably at -10.degree. C. to room temperature for about 1 to 2 hours. A known catalytic reduction reaction can be applied to the dehalogenation reaction.

例えば水、酢酸、メタノール、エタノール、エーテル、
ジオキサン等の溶媒中パラジウム黒、パラジウム炭素、
酸化白金、白金黒、ラネーニツケル等の触媒の存在下に
通常常温常圧下で接触還元すればよい。本発明化合物〔
1〕は、以上のようにして得られる化合物〔■〕をエピ
ハロゲノヒドリンと反応させることにより製造される。
For example, water, acetic acid, methanol, ethanol, ether,
Palladium black, palladium carbon, in a solvent such as dioxane
Catalytic reduction may be carried out usually at room temperature and pressure in the presence of a catalyst such as platinum oxide, platinum black, or Raney nickel. Compound of the present invention [
1] is produced by reacting the compound [■] obtained as described above with epihalogenohydrin.

該反応は、適当な塩基性化合物たとえば水酸化ナトリウ
ム、水酸化カリウム、炭酸ナトリウム、炭酸カリウム、
ナトリウムエトキシド、ナトリウムメトキシド、カリウ
ムエトキシド、カリウムメトキシド、水素化ナトリウム
、金属ナトリウム、金属カリウム等の無機塩基性化合物
あるいはプペリジン、ピリジン、トリエチルアミン等の
有機塩基性化合物等の存在下、無溶媒またはメタノール
、エタノール、イソプロパノール等の低級アルコール類
、アセトン、メチルエチルケトン等のケトン類、エーテ
ル、ジオキサン等のエーテル類、ベンゼン、トルエン、
キシレン等の芳香族炭化水素類及び水等を溶媒として実
施できる。なかでも溶媒としてメタノール、エタノール
等を用いるのが有利である。エピハロゲノヒドリンとし
ては塩素原子、臭素原子または沃素原子等のハロゲン原
子を有する化合物がいずれも用いられ、これらエピハロ
ゲノヒドリンは化合物〔■〕に対して通常等モルないし
過剰量好ましくは5〜1@モル量用い得る。反応か0〜
150℃で進行するが、一般には50〜100℃で行な
うのがよい。エピハロゲノヒドリンは上記反応式1で示
される如く化合物〔■〕と反応し通常該化合物に(2・
3−エポキシ)プロポキシ基および3−ハロゲノー2−
ヒドロキシプロポキシ基を与え、一般に反応生成物は、
之等の混合物として得られる。本発明化合物はかくして
得られる反応生成物〔■〕+〔■〕を特に分離精製する
ことなく混合物のまま引き続き反応式1に従い一般式R
3R4NHで表わされるアミン類と反応させるか、又は
上記反応生成物に、一般に用いられる精製法例えば分別
再結晶法、カラムクロマトグラフィー等を適用して3−
ハロゲノー2−ヒドロキシプロポキシ基を有する化合物
〔■〕を分離精製し、これを上記反応式2の如く引き続
きR3R4NHで表わされるアミン類と反応させること
により製造できる。用いられるアミン類としては具体的
には、メチルアミン、エチルアミン、プロピルアミン、
イソプロピルアミン、Tert−ブチルアミン等の低級
アルキルアミン類、フェネチルアミン、3●4−ジメト
キシフェネチルアミン、2−p−メトキシフェノキシエ
チルアミン、3●4●5−トリメトキシフェネチルアミ
ン、N−ベンジルイソプロピルアミン、1−メチルー2
−フェノキシエチルアミン等のアミン類が挙げられる。
これらアミン類と上記反応生成物との反応は無溶媒でも
行なわれるが、たとえばジオキサン、テトロヒドロフラ
ン等のエーテル類、ベンゼン、トルエン、キシレン等の
芳香族炭化水素のほか水、ジメチルホルムアミド等さら
に好ましくはメタノール、エタノール等の極性溶媒中で
行なうのがよい。アミン類は上記反応生成物に対して過
剰量用いられるが、一般には約6〜8倍モル量を用いる
のがよい。本反応は特に加熱することなく進行するが、
好ましくは約50〜80℃で行なうのがよい。かくして
一般式〔1〕で表わされる本発明の3●4−ジヒドロカ
ルボスチリル誘導体が収得される。
The reaction is carried out using a suitable basic compound such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate,
In the presence of inorganic basic compounds such as sodium ethoxide, sodium methoxide, potassium ethoxide, potassium methoxide, sodium hydride, metallic sodium, metallic potassium, etc. or organic basic compounds such as poperidine, pyridine, triethylamine, etc., without solvent. or lower alcohols such as methanol, ethanol, and isopropanol, ketones such as acetone and methyl ethyl ketone, ethers such as ether and dioxane, benzene, toluene,
This can be carried out using aromatic hydrocarbons such as xylene, water, etc. as a solvent. Among these, it is advantageous to use methanol, ethanol, etc. as the solvent. As the epihalogenohydrin, any compound having a halogen atom such as a chlorine atom, a bromine atom, or an iodine atom can be used, and these epihalogenohydrins are usually used in an equimolar to excess amount, preferably 5 to 1@molar amount can be used. Reaction? 0~
The process proceeds at 150°C, but is generally preferably carried out at 50-100°C. Epihalogenohydrin reacts with compound [■] as shown in reaction formula 1 above, and usually reacts with compound [■] to form (2.
3-epoxy)propoxy group and 3-halogeno 2-
giving a hydroxypropoxy group, the reaction product is generally
It is obtained as a mixture of these. The compound of the present invention is produced by the reaction product [■] + [■] obtained in this way as a mixture without being particularly separated and purified.
The 3-
It can be produced by separating and purifying the compound [■] having a halogeno 2-hydroxypropoxy group, and then reacting it with an amine represented by R3R4NH as shown in Reaction Formula 2 above. Specifically, the amines used include methylamine, ethylamine, propylamine,
Lower alkylamines such as isopropylamine and tert-butylamine, phenethylamine, 3●4-dimethoxyphenethylamine, 2-p-methoxyphenoxyethylamine, 3●4●5-trimethoxyphenethylamine, N-benzylisopropylamine, 1-methyl-2
- Amines such as phenoxyethylamine can be mentioned.
The reaction between these amines and the above-mentioned reaction product can be carried out without a solvent, but for example, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, and xylene, as well as water and dimethylformamide are more preferable. is preferably carried out in a polar solvent such as methanol or ethanol. The amines are used in an excess amount relative to the above reaction product, but it is generally preferable to use about 6 to 8 times the molar amount. This reaction proceeds without any particular heating, but
Preferably, the temperature is about 50 to 80°C. In this way, the 3●4-dihydrocarbostyryl derivative of the present invention represented by the general formula [1] is obtained.

該誘導体は之を酸付加塩とするに当つては常法に従い薬
理的に許容される酸例えば塩酸、硫酸、りん酸、臭化水
素酸等の無機酸、しゆう酸、7マレイン酸、フマール酸
、りんご酸、酒石酸、くえん酸、安息香酸等の有機酸と
反応させればよい。尚本発明の3●4−ジヒドロカルボ
スチリル誘7導体は、光学異性体を包含するものであり
、また9該誘導体からその3・4一位の水素を脱水素し
て、真性のカルボスチリル誘導体とすることもでき、ま
た該誘導体の1位に低級アルキル基、アラルキル基等の
置換基を導入することもでき、かくして得られる真性カ
ルボスチリル誘導体及びN−置換カルボスチリル誘導体
も本発明化合物と同様の薬理活性を期待できる。
The derivatives can be made into acid addition salts using conventional methods using pharmacologically acceptable acids such as inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid, oxalic acid, 7-maleic acid, and fumaric acid. It may be reacted with an organic acid such as acid, malic acid, tartaric acid, citric acid, or benzoic acid. The 3●4-dihydrocarbostyryl derivative 7 of the present invention includes optical isomers, and by dehydrogenating the hydrogen at the 3 and 41 positions from the 9 derivative, a true carbostyryl derivative can be obtained. It is also possible to introduce a substituent such as a lower alkyl group or an aralkyl group into the 1-position of the derivative, and the thus obtained true carbostyryl derivative and N-substituted carbostyryl derivative also have the same properties as the compounds of the present invention. It can be expected to have pharmacological activity.

以下本発明を参考例及び実施例を挙け説明する。The present invention will be described below with reference to Reference Examples and Examples.

参考例1 5−アセトキシー3・4−ジヒドロカルボスチリル20
.5y及び微粉砕した無水塩化アルミニウム26.6y
を密に混合し、油浴上で良くかきまぜながら200℃に
て3時間加熱する。
Reference example 1 5-acetoxy 3,4-dihydrocarbostyryl 20
.. 5y and finely ground anhydrous aluminum chloride 26.6y
Mix thoroughly and heat on an oil bath at 200°C for 3 hours while stirring well.

反応終了後室温まで放冷し、10%塩酸及び氷500y
を加えて分解し1夜放置する。析出した結晶を枦取し、
水1eで洗浄の後、ジオキサンから再結晶して融点27
3〜275.0℃の無定形結晶の8−アセチルー5−ヒ
ドロキシー3・4−ジヒドロカルボスチル17.2fを
得る。参考例2 5−アセトキシー3・4−ジヒドロカルボスチリル20
.5yをクロロホルム500m1に溶解し、室温で攪拌
しながら臭素16.0yをクロロホルム100m1に溶
解した溶液を滴加ロードより少づつ1時間を要して加え
る。
After completion of the reaction, cool to room temperature, add 10% hydrochloric acid and 500y of ice.
Add and disassemble and leave overnight. Collect the precipitated crystals,
After washing with 1e of water, it was recrystallized from dioxane with a melting point of 27.
Amorphous crystalline 8-acetyl-5-hydroxy-3,4-dihydrocarbostyl 17.2f having a temperature of 3 to 275.0°C is obtained. Reference example 2 5-acetoxy 3,4-dihydrocarbostyryl 20
.. 5y was dissolved in 500 ml of chloroform, and while stirring at room temperature, a solution of 16.0 y of bromine dissolved in 100 ml of chloroform was added in smaller portions over a period of 1 hour than the dropwise addition load.

その後3紛加熱還流し、減圧下で濃縮する。エタノール
100m1を加えて放冷し、析出する結晶を枦取し、水
1fで洗浄の後乾燥することによつて無色針状結晶の5
−アセトキシー8ーブロモー3●4−ジヒドロカルボス
チリル24.26Vを得る。このようにして得られた5
−アセトキシー8−ブロモー3・4−ジヒドロカルボス
チリル18.9yを微粉砕無水塩化アルミニウムと密に
混合し、参考例1と同様に反応させ処理することによつ
て融点265〜267.0℃の無色無定形結晶.として
6−アセチルー8−ブロモー5−ヒドロキシー3・4−
ジヒドロカルボスチリル&74yを得る。参多例3 6−アセチルー8−ブロモー5−ヒドロキシー!3●4
−ジヒドロカルボスチリル0.28f1を1N−カセイ
ソーダ水溶液25m1に溶解し、パラジウム黒0.10
gを加え、室温、1気圧で3時間水素を吸収させる。
Thereafter, the three powders were heated to reflux and concentrated under reduced pressure. Add 100 ml of ethanol, let it cool, take off the precipitated crystals, wash with 1 liter of water, and dry to obtain 5.
-acetoxy 8-bromo 3●4-dihydrocarbostyryl 24.26V is obtained. 5 obtained in this way
- Acetoxy 8-bromo 3,4-dihydrocarbostyryl 18.9y was mixed intimately with finely ground anhydrous aluminum chloride, and a colorless product with a melting point of 265 to 267.0°C was obtained by reacting and treating in the same manner as in Reference Example 1. Amorphous crystal. as 6-acetyl-8-bromo-5-hydroxy-3,4-
Dihydrocarbostyril &74y is obtained. Example 3 6-acetyl-8-bromo-5-hydroxy! 3●4
-Dissolve 0.28f1 of dihydrocarbostyril in 25ml of 1N-caustic soda aqueous solution, and dissolve 0.10ml of palladium black.
g and allowed to absorb hydrogen for 3 hours at room temperature and 1 atm.

反応終了後触媒を枦別し、枦液を塩酸酸性として析出す
る結晶を枦取し、水洗の後エタノクールで洗浄して乾燥
することによつて無色無定形結晶として融点249.0
〜250.00Cの6−アセチルー5−ヒドロキシー3
●4−ジヒドロカルボスチリル0.14yを得る。参考
例4 8−アセチルー5−ヒドロキシー3●4−ジヒドロカル
ボスチリル7.0gを塩化メチレン200m1に溶解し
、氷冷下微粉砕無水塩化アルミニウム25yを加え激し
く攪拌する。
After the reaction is completed, the catalyst is separated, the solution is acidified with hydrochloric acid, the precipitated crystals are collected, washed with water and then with ethanol cool, and dried to form colorless amorphous crystals with a melting point of 249.0.
~250.00C 6-acetyl-5-hydroxy-3
●0.14y of 4-dihydrocarbostyryl is obtained. Reference Example 4 7.0 g of 8-acetyl-5-hydroxy-3●4-dihydrocarbostyryl is dissolved in 200 ml of methylene chloride, and 25 y of finely ground anhydrous aluminum chloride is added under ice cooling, followed by vigorous stirring.

氷冷攪拌下、臭素7yを塩化メチレン100m1に溶解
した溶液を滴下ロードより少量づつ加える。添加終了後
1時間同温度で攪拌しその後還流し、臭化水素の発生が
止み、均一系となつた所で終点とし、減圧下で濃縮乾固
すフる。残渣に氷300fI1希塩酸50n1を加えて
分解し、析出した結晶を枦取し、水11で洗浄する。さ
らにメタノールで洗浄の後クロロホルム−メタノールか
ら再結晶して融点238.0〜240.0℃の無色無定
形結晶の8−アセチルー6−ブロモー5−ヒ門ドロキシ
ー・3●4−ジヒドロカルボスチリル6.1yを得る。
参考例5 5−アセトキシー8−クロロー3・4−ジヒドロカルボ
スチリル4.80y1微粉砕無水塩化アルミ・ニウム1
0.0yを密に混合し、油浴上で良くかきまぜながら2
00℃に加熱する。
While cooling with ice and stirring, a solution of bromine 7y dissolved in 100 ml of methylene chloride is added little by little from a dropwise load. After the addition was completed, the mixture was stirred at the same temperature for 1 hour, then refluxed, and the end point was reached when the generation of hydrogen bromide stopped and the system became homogeneous, and the mixture was concentrated to dryness under reduced pressure. The residue is decomposed by adding 300 fl of ice and 50 n1 of diluted hydrochloric acid, and the precipitated crystals are taken out and washed with 11 of water. After further washing with methanol, recrystallization from chloroform-methanol yields colorless amorphous crystals with a melting point of 238.0 to 240.0°C. Get 1y.
Reference example 5 5-acetoxy 8-chloro 3,4-dihydrocarbostyryl 4.80y1 Finely ground anhydrous aluminum chloride 1
Mix 0.0y thoroughly and stir well on an oil bath.
Heat to 00°C.

4時間後室温まで放冷し、氷200f1濃塩酸20m1
を加えて分解し一夜放置する。
After 4 hours, cool to room temperature and add 200ml of ice and 20ml of concentrated hydrochloric acid.
Add it, disassemble it and leave it overnight.

析出した結晶を枦取し、水700m1で洗浄の後、エタ
ノール200m1で洗浄し、クロロホルム−エタノール
から再結晶して融点264.0〜265.0℃の無色無
定形結晶の6−アセチルー8−クロロー5−ヒドロキシ
ー3●4−ジヒドロカルボスチリル3.22fを得る。
参考例6 6−アセチルー8−ブロモー5−ヒドロキシー3・4−
ジヒドロカルボスチリル2.0fをメタノール50m1
に懸濁し、エピク曵レヒドリン20m1及び触媒として
2滴のピペリジンを加えて3時間加熱還流する。
The precipitated crystals were collected, washed with 700 ml of water, washed with 200 ml of ethanol, and recrystallized from chloroform-ethanol to give 6-acetyl-8-chloro as colorless amorphous crystals with a melting point of 264.0-265.0°C. 5-Hydroxy-3●4-dihydrocarbostyryl 3.22f is obtained.
Reference example 6 6-acetyl-8-bromo-5-hydroxy-3,4-
Dihydrocarbostyril 2.0f methanol 50ml
20 ml of Epicurehydrin and 2 drops of piperidine as a catalyst were added, and the mixture was heated under reflux for 3 hours.

反応終了後減圧下で濃縮し、残留物に水50m1を加え
て再度濃縮乾固する。残渣をメタノール50m1に溶解
し不溶部を枦別した後氷冷し析出する結晶を枦取し、冷
メタノールで洗浄の後乾燥して融点174.0〜177
.0℃の無色無定形結晶の6−アセチルー8−ブロモー
5−(3−クロロ2−ヒドロキシ)プロポキシー3・4
−ジヒドロカルボスチリル1.07gを得る。参考例7 6−アセチルー5−ヒドロキシー3●4−ジヒドロカル
ボスチリル4.0yをエピクロルヒドリン50m1に懸
濁させ、トリエチルアミン0.5m1を加え90′Cで
4時間攪拌する。
After the reaction is completed, the mixture is concentrated under reduced pressure, 50 ml of water is added to the residue, and the mixture is again concentrated to dryness. The residue was dissolved in 50 ml of methanol, the insoluble portion was separated, cooled on ice, the precipitated crystals were collected, washed with cold methanol and dried to obtain a solution with a melting point of 174.0-177.
.. Colorless amorphous crystals of 6-acetyl-8-bromo-5-(3-chloro2-hydroxy)propoxy 3,4 at 0°C
-1.07 g of dihydrocarbostyril are obtained. Reference Example 7 4.0 y of 6-acetyl-5-hydroxy-3●4-dihydrocarbostyryl was suspended in 50 ml of epichlorohydrin, 0.5 ml of triethylamine was added, and the mixture was stirred at 90'C for 4 hours.

反応終了後減圧下に濃縮し残留物を氷冷し少量のメタノ
ールを加え結晶化させる。析出した結晶を戸取し、冷メ
タノールで洗浄後メタノールから再結晶して融点173
.0〜176.0℃の無色無定形結晶の6−アセチルー
5一(3−クロロー2−ヒドロキシ)プロポキシー3・
4−ジヒドロカルボスチリル2.64fを得る。参考例
86−アセチルー8−クロロー5−ヒドロキシー3・4
−ジヒドロカルボスチリル2.83yをエピクロルヒド
リン50m1に懸濁し、トリエチルアミン3滴を触媒と
して加え75℃で6時間攪拌する。
After the reaction is completed, the mixture is concentrated under reduced pressure, the residue is cooled with ice, and a small amount of methanol is added to crystallize it. The precipitated crystals were collected, washed with cold methanol, and then recrystallized from methanol to a melting point of 173.
.. Colorless amorphous crystals of 6-acetyl-5-(3-chloro-2-hydroxy)propoxy-3 at 0 to 176.0°C.
4-dihydrocarbostyryl 2.64f is obtained. Reference example 86-acetyl-8-chloro-5-hydroxy-3,4
- 2.83y of dihydrocarbostyryl was suspended in 50ml of epichlorohydrin, 3 drops of triethylamine was added as a catalyst, and the mixture was stirred at 75°C for 6 hours.

反応後了後参考例7で同様に処理しメタノールから再結
晶して融点209.0〜210.0℃の無色無定形結晶
の6−アセチルー8−クロロー5−(3−クロロー2−
ヒドロキシ)プロポキシー3●4−ジヒドロカルボスチ
リル1.00yを得る。実施例1 6−アセチルー8−ブロモー5−(3−クロロー2−ヒ
ドロキシ)プロポキシー3・4−ジヒドロカルボスチリ
ル1.05Vをメタノール10m1に懸濁しIsO−プ
ロピルアミン20m1を加えて8時間加熱還流した。
After the completion of the reaction, the same procedure as in Reference Example 7 was followed and recrystallized from methanol to obtain colorless amorphous crystals of 6-acetyl-8-chloro-5-(3-chloro-2-
1.00 y of hydroxy)propoxy 3●4-dihydrocarbostyryl is obtained. Example 1 1.05 V of 6-acetyl-8-bromo-5-(3-chloro-2-hydroxy)propoxy-3,4-dihydrocarbostyryl was suspended in 10 ml of methanol, 20 ml of IsO-propylamine was added, and the mixture was heated under reflux for 8 hours.

反応終了後減圧下で濃縮乾固し、残渣に濃塩酸10m1
を加えて2時間加熱還流する。その後再度減圧下で濃縮
乾固し、残渣をメタノ−ルーエーテル(1:3)混合溶
媒20m1に加熱溶解する。不溶部を枦別した後、放冷
して結晶化させることによつて融点223.0〜226
.0℃の無色無定形結晶の6−アセチルー8−ブロモー
5−(2−ヒドロキシー3−1S0−プロピルアミノ)
プロポキシー3●4−ジヒドロカルボスチリルを塩酸塩
として0.28yを得る。実施例2 8−アセチルー6−ブロモー5−ヒドロキシー3・4−
ジヒドロカルボスチリル3.0yをエピクロルヒドリン
50m1に懸濁し、ピペリジン2m1を触媒として加え
70℃で4時間攪拌する。
After the reaction was completed, it was concentrated to dryness under reduced pressure, and 10 ml of concentrated hydrochloric acid was added to the residue.
and heated under reflux for 2 hours. Thereafter, the mixture was again concentrated to dryness under reduced pressure, and the residue was heated and dissolved in 20 ml of a methanol-ether (1:3) mixed solvent. After separating the insoluble part, the melting point is 223.0 to 226 by cooling and crystallizing.
.. 6-acetyl-8-bromo-5-(2-hydroxy-3-1S0-propylamino) in colorless amorphous crystals at 0°C
Propoxy 3●0.28y was obtained as 4-dihydrocarbostyryl hydrochloride. Example 2 8-acetyl-6-bromo-5-hydroxy-3,4-
3.0 y of dihydrocarbostyryl was suspended in 50 ml of epichlorohydrin, 2 ml of piperidine was added as a catalyst, and the mixture was stirred at 70° C. for 4 hours.

反応終了後減圧下で濃縮し残留タール状物に水100m
1を加え良くかきまぜた後再度減圧下で濃縮する。残留
物をメタノール100m1溶解し、不溶部を枦別した後
、50m1まで濃縮し氷冷する。析出した原料結晶をp
別する。かくして得られた枦液にIsO−プロピルアミ
ン50mLを加え7時間加熱還流する。反応終了後減圧
下で濃縮乾固し、残渣を希塩酸に溶解し不溶部を枦別す
る。枦液を脱色した後減圧下で濃縮乾固し、残渣をエタ
ノール50m1に溶解し、エーテルを白濁するまで加え
て放冷する。析出する結晶を枦別し、戸液を氷冷して結
晶化させることにより融点193.0〜196.0℃(
分解)の無色無定形結晶の8−アセチルー6−ブロモー
5−(2−ヒドロキシー3−1S0−プロピルアミノ)
プロポキシー3●4−ジヒドロカルボスチリルを塩酸塩
として1.2yを得る。実施例3 6−アセチルー5−(3−クロロー2−ヒドロキシ)プ
ロポキシー3・4−ジヒドロカルボスチリル1.6yを
メタノール50m1に懸濁し、Tert−ブチルアミン
50m1を加えて7時間加熱還流する。
After the reaction is complete, concentrate under reduced pressure and add 100ml of water to the remaining tar.
After adding 1 and stirring well, concentrate again under reduced pressure. The residue was dissolved in 100 ml of methanol, the insoluble portion was separated, and the solution was concentrated to 50 ml and cooled on ice. The precipitated raw material crystals are
Separate. 50 mL of IsO-propylamine was added to the thus obtained molasses liquid, and the mixture was heated under reflux for 7 hours. After completion of the reaction, the mixture was concentrated to dryness under reduced pressure, the residue was dissolved in dilute hydrochloric acid, and the insoluble portion was separated. After decolorizing the licorice, it was concentrated to dryness under reduced pressure, the residue was dissolved in 50 ml of ethanol, ether was added until it became cloudy, and the mixture was allowed to cool. The precipitated crystals are separated, and the liquid is cooled with ice to crystallize, resulting in a melting point of 193.0-196.0°C (
Colorless amorphous crystals of 8-acetyl-6-bromo-5-(2-hydroxy-3-1S0-propylamino)
Propoxy 3●1.2y is obtained by converting 4-dihydrocarbostyryl into hydrochloride. Example 3 1.6y of 6-acetyl-5-(3-chloro-2-hydroxy)propoxy-3,4-dihydrocarbostyryl is suspended in 50ml of methanol, 50ml of tert-butylamine is added, and the mixture is heated under reflux for 7 hours.

反応終了後減圧下で濃縮乾固し残渣を希塩酸50TfL
tに溶解し不溶部を枦別する。淵液を10%カセイソー
ダ水溶液でPH約10に調整した後クロロホルム200
m1で抽出する。クロロホルム抽出液を水洗した後減圧
下でクロロホルムを留去し、残渣をエタノール100m
Lに溶解し脱色する。この溶液にしゆう酸のアセトン溶
液を加えてPH約4に調整し放冷する。析出する結晶を
洒別した後淵液を減圧下で濃縮乾固し残渣をエタノール
から再結晶することにより融点234.0〜237.0
℃の無色無定形結晶の6ーアセチルー5−(3−Ter
t−ブチルアミノー2ーヒドロキシ)プロポキシー3・
4−ジヒドロカルボスチリルをしゆう酸塩として0.6
1fを得る。・実施例4〜10上記実施例1〜3のいず
れかと同様にして下記第1表記載の各化合物を得る。
After the reaction was completed, the residue was concentrated to dryness under reduced pressure and diluted with 50 TfL of diluted hydrochloric acid.
Dissolve in water and separate the insoluble part. After adjusting the pH of the deep water to about 10 with a 10% caustic soda aqueous solution, 200 ml of chloroform was added.
Extract with m1. After washing the chloroform extract with water, chloroform was distilled off under reduced pressure, and the residue was dissolved in 100 ml of ethanol.
Dissolve in L and decolorize. An acetone solution of citric acid was added to this solution to adjust the pH to about 4, and the solution was allowed to cool. After separating the precipitated crystals, the aqueous solution was concentrated to dryness under reduced pressure, and the residue was recrystallized from ethanol to give a melting point of 234.0 to 237.0.
6-acetyl-5-(3-Ter) in colorless amorphous crystals at ℃
t-Butylamino-2-hydroxy)propoxy 3.
4-dihydrocarbostyryl as oxalate 0.6
Obtain 1f. - Examples 4 to 10 Each compound listed in Table 1 below was obtained in the same manner as in any of Examples 1 to 3 above.

第1表は得られた化合物を下記に従う置換基で示す。夫
々の化合物につきその製造方法、再結晶溶媒及び融点を
第2・表に示す。次に、本発明化合物及び従来化合物に
ついて、抗高血圧薬としての薬理試験(降圧作用の試験
)を行なつた。
Table 1 shows the compounds obtained with substituents according to the following. Table 2 shows the manufacturing method, recrystallization solvent, and melting point of each compound. Next, the compounds of the present invention and conventional compounds were subjected to pharmacological tests as antihypertensive agents (tests for antihypertensive action).

薬理試験法 体重9.7〜19.0k9の雑種成犬5頭を雌雄の別な
く用いた。
Pharmacological Test Method Five adult mongrel dogs, both male and female, weighing 9.7 to 19.0 kg were used.

ペントバルビタールナトリウムの30Tn91k9の静
脈内注射て麻酔して背位に固定し、左側の大腿動脈及び
大腿静脈を露出した。静脈にビニルカテーテルを挿入し
、へバリン100峰位/Kgを静注した。その後動脈内
に挿入したビニルカテーテルを電気血圧計に連結して血
圧(]C!Hg)を測定した。供試化合物は、0.9%
生理的食塩水に溶解し、その0.1、1.0、10及び
100μGlk9を5〜1紛間隔で累積的に静注により
投与した。試験結果を、第3表に示す。
The animals were anesthetized with an intravenous injection of pentobarbital sodium 30Tn91k9, fixed in a dorsal position, and the left femoral artery and vein were exposed. A vinyl catheter was inserted into the vein, and 100 peaks/kg of Hebalin was intravenously injected. Thereafter, a vinyl catheter inserted into the artery was connected to an electric sphygmomanometer to measure blood pressure (]C!Hg). The test compound is 0.9%
0.1, 1.0, 10, and 100 μGlk9 was dissolved in physiological saline and cumulatively administered intravenously at intervals of 5 to 1 dose. The test results are shown in Table 3.

表中の数値は、供試化合物の静注前の血圧から各投与量
を静注後の降圧値(MHg)を示す。− −ーーーー
ー − −]? 供試化合物 −ー −ーー − 1′ 0H 2JHCH2NHCH2−0 コ0 ・HC2− H 明化合物は従来化合物に比べ ある・ 用を有することが、明らかで Tg/Ki−ーー ? [ ” ? 従来化合物 012(特開昭49? 一101388号) [ ?
The numerical values in the table indicate the blood pressure reduction value (MHg) after intravenous injection of each dose from the blood pressure before intravenous injection of the test compound. - - - - -]? Test compound - - - - - 1' 0H 2JHCH2NHCH2-0 Co0 ・HC2-H It is clear that the light compound has a certain effect compared to the conventional compound. [ ” ? Conventional Compound 012 (Japanese Unexamined Patent Publication No. 49-1101388) [ ?

Claims (1)

【特許請求の範囲】 1 一般式 ▲数式、化学式、表等があります▼ 〔式中R_1は水素原子又はハロゲン原子、R_2はア
セチル基、並びにR_3及びR_4はいずれか一方が水
素原子を、他方が低級アルキル基、アルキル部分の炭素
数が1〜6であるフェニルアルキル基、フェニル環上に
低級アルコキシ基を有しアルキル部分の炭素数が1〜6
であるフェニルアルキル基又はフェニル環上に低級アル
コキシ基を有しアルキル部分の炭素数が1〜6であるフ
ェノキシアルキル基を示す。 〕で表わされる3・4−ジヒドロカルボスチリル誘導体
[Claims] 1 General formula ▲ Numerical formulas, chemical formulas, tables, etc. A lower alkyl group, a phenylalkyl group whose alkyl moiety has 1 to 6 carbon atoms, a lower alkoxy group on the phenyl ring and whose alkyl moiety has 1 to 6 carbon atoms
represents a phenylalkyl group or a phenoxyalkyl group having a lower alkoxy group on the phenyl ring and having 1 to 6 carbon atoms in the alkyl moiety. ] A 3,4-dihydrocarbostyryl derivative represented by:
JP51104091A 1976-08-30 1976-08-30 Novel 3,4-dihydrocarbostyryl derivative Expired JPS6053016B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP51104091A JPS6053016B2 (en) 1976-08-30 1976-08-30 Novel 3,4-dihydrocarbostyryl derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51104091A JPS6053016B2 (en) 1976-08-30 1976-08-30 Novel 3,4-dihydrocarbostyryl derivative

Publications (2)

Publication Number Publication Date
JPS5328180A JPS5328180A (en) 1978-03-16
JPS6053016B2 true JPS6053016B2 (en) 1985-11-22

Family

ID=14371442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51104091A Expired JPS6053016B2 (en) 1976-08-30 1976-08-30 Novel 3,4-dihydrocarbostyryl derivative

Country Status (1)

Country Link
JP (1) JPS6053016B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61293241A (en) * 1985-06-20 1986-12-24 Eiwa Kasei Kogyo Kk Electrically conductive elastomer composition containing vulcanized rubber powder
JPS63290821A (en) * 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd Antiarrhythmic
US5654317A (en) * 1992-09-18 1997-08-05 Otsuka Pharmaceutical Company, Limited Antiarrhythmic agent
JPH07252153A (en) * 1995-01-25 1995-10-03 Otsuka Pharmaceut Co Ltd Antiarrhythmic agent

Also Published As

Publication number Publication date
JPS5328180A (en) 1978-03-16

Similar Documents

Publication Publication Date Title
US4855298A (en) 6-Halo-1,2,3,4-tetrahydroquinazoline-4-spiro-4-imidazolidine-2,2'5'-triones useful for the treatment and prophylaxis of diabetic complications
EP0179383B1 (en) 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
US5708020A (en) Arylalkyl(thio)amides
JPS609713B2 (en) carbostyril derivatives
JPS6044308B2 (en) Production method of chroman derivatives
EP0165422B1 (en) Substituted bis-(4-aminophenyl)-sulphones, their preparation and their use as medicines
JPS6053016B2 (en) Novel 3,4-dihydrocarbostyryl derivative
KR950011748B1 (en) Sulfenamide derivatives and their production
JPS5913510B2 (en) Calbostyril Yudou Tainoseizohou
US4208410A (en) Dibenzo[d,g][1,3,6]dioxazocine derivatives
US4507308A (en) Analgesically or anti-inflammatory effective 4-quinolyl anthranilic acid derivatives
US4108894A (en) Amidines
KR930003611B1 (en) Process for preparation of quinolonecarboxylic acid derivatives
KR860001583B1 (en) Process for the preparation of quinoxalinedinedione
US3875176A (en) 2-benzoyl -3-amino-pyridines
Cressman et al. One-Step Synthesis of Polyalkyl-2-iodo-p-benzoquinones
US4478820A (en) Anilino-substituted isoquinoline quinones, pharmaceutical compositions and method of use thereof
JPH0710863B2 (en) Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament
Adams et al. Quinone imides. XIV. Addition of hydrogen chloride to p-quinonedibenzimides and related compounds
JPH04169583A (en) Phenothiazine derivative and its production
GB1561153A (en) Process for the preparation of thiochroman derivatives
JPS6183172A (en) Dibenzo (b,f) (1,5) oxazocine derivative, its preparation, and pharmaceutical containing said derivative as active component
US4816461A (en) 7,8,9,10-tetrahydrothieno[3,2-e]pyrido[4,3-b] indole, a process for their preparation and medicaments containing them
KR810001887B1 (en) Process for preparing phenylethylamines
KR810001891B1 (en) Process for preparing pheylethylamines